id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0611-0065,FDA,FDA-2011-D-0611,"New and Revised Draft Q&As on Biosimilar Development and the
Biologics Price Competition and Innovation Act (Revision 2); Draft
Guidance for Industry; Availability",Notice,Notice of Availability,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,2019-02-12T04:59:59Z,2019-11-18T16:51:35Z,2018-26852,0,0,0900006483987c81
FDA-2011-D-0611-0064,FDA,FDA-2011-D-0611,"Biosimilars: Questions and Answers on Biosimilar Development and the
Biologics Price Competition and Innovation Act of 2009; Guidance for
Industry; Availability",Notice,Notice of Availability,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,,2018-12-12T15:04:52Z,2018-26853,0,0,0900006483987c7c
FDA-2011-D-0611-0067,FDA,FDA-2011-D-0611,Questions and Answers on Biosimilar Development and the BPCI Act; Guidance for Industry,Other,Guidance,2018-12-11T05:00:00Z,2018,12,2018-12-11T05:00:00Z,,2024-11-12T22:53:26Z,,1,0,0900006483988a7d
FDA-2011-D-0611-0066,FDA,FDA-2011-D-0611,"New and Revised Draft Q&As on Biosimilar Development and the BPCI
Act (Revision 2); Guidance for Industry; Draft Guidance",Other,Guidance,2018-12-11T05:00:00Z,2018,12,2018-12-11T05:00:00Z,,2024-11-12T22:53:26Z,,1,0,0900006483988a81